Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 and Bevacizumab in Refractory Solid Tumors and GBM
NCT01349660Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Dec 2011
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of buparlisib in glioblastoma multiforme (GBM), solid tumor, sponsored by SCRI Development Innovations. Started Dec 2011; status: completed.
02
Drugs
buparlisib
03
Conditions
glioblastoma multiforme (GBM)solid tumor
Beyond the preview
Go deeper on NCT01349660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01349660.